Streetbeat News

ASPHF

Ascentage Pharma Group International

https://www.ascentagepharma.com

Industry

Research and Development in Biotechnology

Open

6.45

Mkt cap

843M

Volume

100

High

6.45

P/E Ratio

-5.85

52-wk high

6.45

Low

2.69

Div yield

N/A

52-wk low

2.35

Ascentage Pharma Group International (OTC:ASPHF) has entered into a partnership with Takeda International, giving Takeda an option to market Ascentage's leukemia drug, olverembatinib, outside of China and Russia. The deal includes an initial payment of $100 million and potential milestone payments up to $1.2 billion. Takeda has also taken a 7.73% equity stake in Ascentage. This partnership alleviates Ascentage's liquidity crisis and boosts investor confidence, as evidenced by a significant rise in its stock price.

Portfolio Pulse from The Bamboo Works

June 27, 2024 | 4:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.